KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomized, Double-Blind, Placebo-controlled Phase III Trials (ORBIT 3 and ORBIT 4).

Rebecca C Hull, Jamie Stobo, Hani Abo-Leyah, Hollian Richardson, Daniela Alferes de Lima Headley, Merete B Long, Chandani Hennayake, Amy Gilmour, Emma D Johnson, Michael Tunney, Alison J Dicker, Eleanor Kewin, Jeffrey T J Huang, Charles S Haworth, James D Chalmers

Am J Respir Crit Care Med 211(8) 1397-1408

PMID40664229
PMCIDPMC12369955
DOI10.1164/rccm.202501-0159OC
发表日期2025-07-15
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:生活质量量表图;Figure 2:森林图/亚组分析图;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 forest plot。
摘要

摘要

Rationale: Replicate phase III trials of inhaled antibiotics in patients with bronchiectasis have produced inconsistent results. Objectives: This study investigated if different microbial and inflammatory endotypes are linked to antibiotic response in patients with chronic Pseudomonas aeruginosa infection. Methods: ORBIT-3 and ORBIT-4 were phase III trials of inhaled liposomal ciprofloxacin compared with placebo in patients with bronchiectasis with chronic P. aeruginosa infections. Baseline sputum from the trials were analyzed by 16S rRNA sequencing (LoopSeq) (n = 377), proteomics (n = 164), and Olink (n = 117). Relationships with clinical features and frequency of exacerbations during the trials were analyzed. Measurements and Main Results: Patients with P. aeruginosa infections demonstrated heterogeneous endotypes. Reduced microbiota diversity was associated with exacerbation frequency (P = 0.021) and quality of life (P = 0.012). Increased exacerbations were associated with increased Pseudomonas abundance and neutrophilic inflammation; decreases in the relative abundance of commensals, including Rothia; and B-cell responses. Geographical differences were observed, with increased microbiota diversity and decreased neutrophilic inflammation in Central Europe. Candidate biomarkers for treatment response were identified, including neutrophil elastase, LSP1, and Rothia relative abundance. Before adjustment, treatment estimates of the two trials varied (ORBIT-3 rate ratio [RR], 0.85 [0.65-1.12], ORBIT-4 RR, 0.63 [0.48-0.82]). After linear discriminant analysis to adjust for microbiota profile and geographical region, the treatment estimates of ORBIT-3 (RR, 0.81 [0.54-1.22]) and ORBIT-4 (RR, 0.82 [0.56-1.22]) were similar and consistent with previous meta-analyses of inhaled antibiotics in bronchiectasis. Conclusions: Patients with chronic P. aeruginosa have heterogeneous microbiota and inflammatory profiles, influencing antibiotic treatment responses in bronchiectasis. Future trials could be improved by patient stratification, including accounting for geographical differences and biomarkers to represent microbiota differences.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Microbiota diversity of Pseudomonas infections in bronchiectasis. ( A–C ) Bray-Curtis PC analysis of microbiota data ( n = 377) annotated by ( A ) Pseudomonas relative abundance, ( B ) patients’ number of exacerbations over 12 months, and ( C ) tertiles of patients’ Quality-of-Life Bronchiectasis Respiratory Symptom Scale scores. Ellipses represent the 95% confidence level for a multivariate t -distribution. ( A–C ) Statistical analysis by permutational ANOVA test, adjusting for clinical factors. ( D and E ) Random forest plots of genera that differ between ( D ) exacerbation categories or ( E ) quality-of-life tertiles. Keys show relative proportions in each group. PC = principal coordinate.
非 KM Figure
Figure 2Figure 2. Profile of the microbiota in ORBIT-3 and -4, relationship of microbiota characteristics to clinical parameters and differences between countries. ( A ) Estimated rate ratio of an exacerbation for a 0.1 (absolute) increase in relative abundance of each taxon/genus; a 10-unit increase in age, body mass index, and FVC (predicted); males versus females (sex); and the four study geographical regions relative to Australia/New Zealand. Adjustment has been made for study, arm, and an arm-by-study interaction. The logarithm of time on treatment is included as an offset. Rate ratios >10 or <0.05 have been excluded for clarity. ( B ) Mean relative abundance of genera in each trial and study arm. Genera shown have at least 1% mean relative abundance; if not, they are classified as “other.” ( C–E ) Random forest plots of genera and patient characteristics that differ between ( C ) all four arms across ORBIT-3 and -4, ( D ) treatment and placebo arms within ORBIT-3, and ( E ) treatment and placebo arms within ORBIT-4. ( F–I ) Pseudomonas relative abundance and Shannon diversity index by trial and treatment arm, together with expected numbers of exacerbations from negative binomial regression models accounting for treatment effect varying with Pseudomonas abundance and Shannon index. ( J ) Shannon diversity of patients in each geographical region, by trial and treatment arm.
非 KM Figure
Figure 3Figure 3. Relationship between the baseline proteome in patients infected with Pseudomonas and patients’ microbiota. ( A ) Principal component (PC) analysis of baseline sputum proteomics ( n = 164) with ( B ) a loading plot showing the top 20 contributing variables and direction of increasing levels. ( C ) PC analysis of A with k -means clustering: cluster 1 ( n = 84), cluster 2 ( n = 39), and cluster 3 ( n = 41). ( D ) Mean relative abundance of genera for proteomic clusters in C . Genera with at least 1% mean relative abundance in each cluster are shown; if not, they are classified as “other.” Cluster 1 ( n = 82), cluster 2 ( n = 37), and cluster 3 ( n = 36). ( E and F ) Volcano plots of false discovery rate–corrected linear models for protein expression by ( E ) patients’ α-diversity measured by Shannon index or ( F ) patients’ Pseudomonas relative abundance. Red dots indicate P < 0.05. PA = P. aeruginosa .
非 KM Figure
Figure 4Figure 4. Proteomic predictors of patient outcomes, diversity in treatment groups, and geographical variation. ( A ) Estimated rate ratio of an exacerbation for a 1 (absolute) increase in relative abundance of each protein. Adjustment has been made for arm interactions. The logarithm of time on treatment is included as an offset. ( B ) Principal component (PC) analysis in Figure 3A grouped by patients’ geographical region. Ellipses represent the core area for each group with 68% confidence interval. ( C ) PC1 from Figure 3A for patients in each geographical region and treatment group.
非 KM Figure
Figure 5Figure 5. Adjustment of baseline microbiota parameters in exacerbation frequency analysis. Exacerbation frequency analysis as in Haworth and colleagues (10), with further adjustment for covariates previously identified as potential confounding factors to explore the sensitivity of the estimated treatment effect. Analyses presented separately for ( A ) the subset of patients with microbiota data and ( B ) the intention-to-treat population. Published estimates from Haworth and colleagues (10) are provided in A and B for reference. Adjustment for geographical region and/or microbiota (LDA) profile results in much more consistent treatment effect estimates from each trial ( A ), suggesting that heterogeneity in the microbiota profile can partly explain the discrepancy in the efficacy of inhaled antibiotics. Although microbiota adjustment cannot be performed in the intention-to-treat dataset, adjustment for geographical region (which is related to microbiota profile) gives similar results ( B ). CI = confidence interval; LDA = linear discriminant analysis; NMDS = non-metric multidimensional scaling; RR = rate ratio.
非 KM Figure